Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Stepwise Management of Chronic Spontaneous Urticaria (CSU) Using Updated International Guidelines
Description
The talk reviews updated international guidelines for chronic spontaneous urticaria (CSU) using a simple stepwise approach. First-line therapy is a standard-dose second-generation H1 antihistamine, which can be increased up to four times daily if needed; antihistamines work best when taken consistently to prevent hives rather than treat already active lesions. The speaker emphasizes avoiding unnecessary complexity, preferring one second-generation agent rather than mixing multiple antihistamines, and notes that first-generation drugs (like diphenhydramine, hydroxyzine, and doxepin) are sedating and should generally be minimized because of sleepiness, dependence, and possible long-term dementia risk. He also discourages routine use of H2 blockers and leukotriene inhibitors because they add pill burden without clear benefit. Disease control should be monitored with tools such as UAS7, the Urticaria Control Test, itch scores, and photo logs. If symptoms remain uncontrolled after an adequate trial of high-dose antihistamines, the next step is advanced therapy such as omalizumab, remibrutinib, or dupilumab; omalizumab and remibrutinib tend to reduce itch quickly, while dupilumab is effective but slower. For refractory cases, older immunosuppressants like cyclosporine, methotrexate, azathioprine, or mycophenolate remain options. Practical pearls include counseling patients about off-label antihistamine dosing, managing cost through big-box stores or online retailers, using pill boxes and phone reminders, continuing antihistamines initially with biologics then tapering as control improves, and recognizing that topical steroids usually have limited value because CSU is a deeper dermal process.
View moreConclusions
- Chronic spontaneous urticaria is best managed with a stepwise, guideline-driven approach that starts with second-generation antihistamines and escalates only if control remains inadequate.
- Up-dosing second-generation antihistamines to as much as four times the standard dose is generally more effective than switching prematurely to other low-yield add-on medications.
- Second-generation antihistamines are preferred over first-generation agents because they are less sedating and avoid the safety concerns associated with long-term first-generation use.
- Omalizumab, remibrutinib, and dupilumab can all produce meaningful itch reduction in patients who fail antihistamines, with omalizumab and remibrutinib often showing faster responses than dupilumab.
- For refractory disease, older immunosuppressive agents such as cyclosporine, methotrexate, azathioprine, and mycophenolate remain fallback options when newer therapies are unavailable or ineffective.
- Routine monitoring of disease activity with simple tools like the Urticaria Control Test, itch scores, and photo journals helps guide treatment escalation and assess response.
- Patient adherence and education are crucial because CSU treatment often requires multiple daily pills, cost considerations, and reassurance that higher antihistamine doses are still guideline-supported.
- Topical steroids generally have limited value in CSU because the disease process is primarily dermal rather than epidermal.
- Tiligada E, BPS 2018